Panel Discussion at OIS@ASRS 2016. Co-Moderated By: Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus Mark Humayun, MD Participants: Mark Blumenkranz, MD Adnan Butt, Biotech Analyst – RBC Capital Markets Donald D’Amico, MD Pravin Dugel, MD Peter Kaiser, MD Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

1. 1. Therapeutic promise of the targets and
proposed mechanisms of action just
presented?
Other promising approaches not presented?

2. 2. From a clinical perspective, where is the
unmet need in DME and wet
AMD? Neuroprotection, anti-fibrosis, anti-
permeability, anti-angiogenesis, other?

3. 3. As these and other phase 2/3 trials approach
proof of concept, what will represent a clinically
meaningful visual improvement above and
beyond anti-VEGF-A therapy? A mean
improvement of 4-5 letters? Injection
burden? Other?

4. 4. Assuming approval of one or more of the
discussed drugs as add-on or adjunctive
therapy, how will this impact patient flow and
injection practices?
What will retina practices look like in 2020?